The objective of this cross-sectional study was to validate an abridged version of the Anosognosia Questionnaire-Dementia (AQ-D) for screening anosognosia in daily practice. The authors reduce the AQ-D from 30 items to 9, with a large sample (n ¼ 352) of patients with Alzheimer disease (AD). The Cronbach a was .793 and an area under the receiver-operating characteristic curve was 0.946. The k index between new abridged AQ-D (AAQ) and original AQ-D was .800. The AAQ presents good validity and reliability indicators and kept concordance with the original scale. It is quick and easy to administer and it can simplify the clinical screening of anosognosia in patients with AD.
Introduction
The construct of anosognosia in dementia is evolving very fast, and although some studies analyze the neurological and neuropsychological correlates of anosognosia in cognitive impairment, others use the latest neuroimaging technologies to identify structural or functional disruptions that may explain the lack of disease awareness in some patients with Alzheimer disease. [1] [2] [3] [4] Consequences of anosognosia on both the patient and the caregiver are widely known. In 1914, Babinski 5 described this disorder in patients with poststroke hemiplegia, and later on, it has been described in a variety of pathologies. [5] [6] [7] [8] The prevalence of anosognosia ranges between 11% and 70% in Alzheimer disease and has been associated with more severe cognitive impairment although it can be seen in early stages too. 9, 10 Anosognosia has also been associated with increased frequency and severity of behavioral and psychological symptoms of dementia (BPSD), mainly with apathy, disinhibition, irritability, and delusions. [11] [12] [13] The main consequences of anosognosia are increased risk behaviors, lower treatment adherence, and increased difficulties for the family to manage the patient. In this sense, the presence of anosognosia has been associated with higher caregiver burden and increased institutionalization. [14] [15] [16] Given the significant impact of anosognosia on the patients and their environment, performing a systematic assessment in clinical practice would be advisable. However, there is a lack of quick and reliable tools to perform a screening, which would allow selecting those patients requiring further evaluation of anosognosia and its clinical consequences. Among the available tools to assess anosognosia, there are some brief classic subjective scales, such as the Experimenter Rating Scale or the Anosognosia Rating Scale, but they require the physician to perform a wide exploration before a classification can be made. 17, 18 Usually, the questionnaires for the assessment of anosognosia analyze the discrepancies detected between the patient's and the caregiver's reports. 9 Among these scales, the most commonly used, especially in research, is the Anosognosia Questionnaire-Dementia (AQ-D) because it includes a cognitive and functional assessment of the patient and also takes into consideration the changes in behavior. 19, 20 Nevertheless, this questionnaire has 30 items and its administration requires too much time to be used as a routine screening tool.
Therefore, the aim of this study was to confirm that the abbreviated version of the AQ-D is a valid instrument to screen for the presence of anosognosia in concordance with the original questionnaire, which would provide a tool allowing a quick and reliable diagnosis of anosognosia in clinical practice.
Methods Design
A cross-sectional, observational, and analytical study.
Patients
The sample set comprised patients with mild, moderate, and severe AD who were diagnosed at 2 different memory clinics (Hospital Santa Caterina [HSC] 21 who had a close, reliable caregiver capable of answering the questions about their states, and who were not institutionalized, were included. The study protocol was approved by the institutional review board of each hospital and all the participants signed the informed consent form.
Procedure and Instruments
In a single study visit, patients were assessed by a trained psychologist who scored the patients according to a scale (described subsequently), administered questionnaires, and registered the clinical information from the clinical chart of each patient.
The AQ-D is a questionnaire comprised of 30 Likert-type response items with 4 response options (never, sometimes, often, and always), with a score ranging from 0 to 90 points. The presence of anosognosia is determined by a difference between the caregiver's and the patient's score greater than 32 points. The AQ-D has a high internal consistency (Cronbach a ¼ .91) and a good interexaminer reliability (Charlson comorbidity index ¼ 0.90). 20 The factor structure includes 2 factors, a cognitive-functional factor and a behavioral factor, which explain 38.9% of the total variance. 19 The data on the sociodemographic characteristics (age, gender, scholarship, civil status, and place of residence) of patients and caregivers were collected in a standardized questionnaire. The clinical assessment of patients was carried out using the following 4 scales. The Mini-Mental State Examination (MMSE) is a screening test for cognitive impairment. It has a score range of 0 to 30, with a lower score indicating greater cognitive impairment. 22 The Disability Assessment in Dementia (DAD) 23 is a specific functional disability assessment scale for patients with dementia that is administered to the caregiver. It is comprised of 40 dichotomous (yes/no) questions that assess the ability of the patient to execute 17 basic activities of daily living and 23 instrumental activities. ''Yes'' is scored as 1 and ''no'' is scored as 0, giving a score range of 0 to 40 points. The Neuropsychiatric Inventory (NPI) 24 is a validated method for the assessment of the presence of BPSD. It is filled out by the caregiver and consists of 12 subscales in which the frequency and severity of delusions, hallucinations, agitation, depression/dysphoria, anxiety, euphoria, apathy, disinhibition, irritability, motor disturbances, sleep disorders, and eating disorders are assessed. The score is the product of the frequency (range ¼ 1-4) and the severity (range ¼ 1-3) of the symptoms, with the total score ranging from 0 to 144 points. The Global Deterioration Scale (GDS), 25 which ranges from 1 (no cognitive decline) to 7 (severe cognitive decline), assesses the stage of disease progression of the patient with dementia. The GDS-4 includes cases of mild dementia, the GDS-5 includes cases of moderate dementia, and the GDS-6 includes cases of moderate-severe dementia.
Statistical Analysis
An extensive analysis of the results was performed by both absolute and relative frequencies for qualitative variables or by central tendency and dispersion measurements for quantitative variables.
New variables were created from the difference between the caregiver's and the patient's score in each of the 30 Likert-type response items. From these new variables, we carried out an exploratory factor analysis (EFA) with Promax rotation (which allows for correlation between the factors) and constraining the resulting factor structure to 2 factors, to maintain the structure of the original scale. 18 We constructed the abridged questionnaire by selecting the variables with an absolute difference in the eigenvalues of the 2 factors !0.60.
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The internal consistency of the abridged questionnaire was evaluated using the Cronbach a coefficient. The level of acceptable reliability was an a coefficient !.7. A new EFA of the abbreviated questionnaire was carried out to compare the factor structure with the original AQ-D factor structure. To determine the cutoff points for the abridged questionnaire, receiver-operating characteristic (ROC) curves were used. The area under the curve (AUC), as well as the sensitivity and specificity of each cutoff point, was determined for all adjusted ROC curves. The optimal cutoff point was established based on the maximum sum of sensitivity and specificity.
We compared the validity of the criteria for the AQ-D and the abridged AQ-D (AAQ) by calculating the k index. The convergent validity and discriminant validity were assessed by calculating the Pearson or Spearman correlation coefficient with the MMSE, DAD, and NPI scales for the overall score of the abridged questionnaire and the score of each factor.
The results are expressed as absolute numbers, percentages, averages, standard deviations (SDs), and 95% confidence intervals (CIs). The level of statistical significance was set at 0.05 to test hypotheses. All data processing and analysis were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago).
Results
We studied a sample of 352 patients with AD, 69% of which were women, with a mean age of 79.2 years (SD ¼ 6.6), of which 53.5% of the patients had a level of education below basic studies, 36.4% had primary studies, and 9.9% had middle or higher studies. The mean age of the primary caregivers was of 61.4 years (SD ¼ 13.7). Most were women (69.3%), and 43.8% of the caregivers were the patients' spouses, and the rest were the children (51.0%) or other relatives (5.2%). The clinical and sociodemographic data of the sample are described in Table 1 .
The mean score in the AQ-D was 29.4 points (SD ¼ 20.3; range ¼ À19.0-88.0). The prevalence of anosognosia according the AQ-D score (discrepancy !32 points) was 45.7% (95% CI ¼ 41.0-52.5).
The FA applied to the AQ-D explained 56.2% of the variance. There were 9 items with an eigenvalue difference !0.60 between 2 factors and these items were selected as representative questions from the abbreviated AQ-D scale ( Table 2 ). The wording of each of the 9 items of the new AAQ is also shown in Table 2 .
The EFA applied to the AAQ also grouped the items into 2 factors, explaining 57.9% of the variance and maintaining the factor structure of the original AQ-D. The internal consistency of the AAQ was within acceptable limits (Cronbach a ¼ .793). For the first factor, the Cronbach a was .815 and the second factor was .627, with an AUC of 0.946. The presence of anosognosia was established when there was a difference of !13 points between the caregiver's and patient's responses, with a sensitivity and specificity that when compared to the original scale was above 0.8 (0.909 and 0.859, respectively).
The prevalence of anosognosia diagnosis with the AAQ was 47.2% (95% CI ¼ 41.8-52.5). When compared side by side with the AQ-D, the validity of the criteria for the AAQ was acceptable, with a k index ¼ .800 (95% CI ¼ 0.737-0.863). Figure 1 shows the ROC curve for the AAQ (AUC ¼ 0.946). Since samples from 2 different sites were available, a comparative study was carried out separately using the data from each site. The results showed agreement for both HSC and HUB, k ¼ .800 and k ¼ .776, respectively. The analysis of the construct discriminant validity of the factors showed an inverse correlation between MMSE scores and the first factor (cognitive and functional) in both patients with anosognosia (Spearman r ¼ À.215; P ¼ .015) and without (Spearman r ¼ À.194; P ¼ .008). Similar results were obtained between the DAD scale and the first factor for patients with (Spearman r ¼ À.314; P < .001) and without (Spearman r ¼ À.184; P ¼ .012) anosognosia. A direct correlation was detected between the second factor (behavioral) and the NPI scores in patients with and without anosognosia (Spearman r ¼ .445; P < .001 and Spearman r ¼ .198; P ¼ .007, respectively), and it was stronger in the former. In the analysis of the construct discriminant validity, the AAQ score showed significant differences in each of the stages of the GDS (F ¼ 34.6; gl ¼ 2; P < .001). Spearman correlation coefficients were moderate to high with the NPI scale (r ¼ .573; P < .001) and the DAD scale (r ¼ À.333; P < .001) and, to a lesser extent, with the MMSE (r ¼ À.167; P ¼ .002). Regarding sociodemographic characteristics, the previously detected differences using the original scale were still observed; thus, patients with anosognosia were older (Mann-Whitney U ¼ 12 313.0; P ¼ .008), but no differences in the gender, civil status, and education were detected (gender: chi-square [ 
Discussion
Anosognosia is frequently diagnosed in those having AD. Despite this, it is poorly studied in daily clinical practice, mainly due to the lack of defined diagnostic criteria. Specifically, there is disagreement on whether to consider anosognosia a focal or global disorder as well as there being a discrepancy between the dimensional and dichotomic (presence/absence) assessments. [27] [28] [29] These aspects are directly associated with the use of different methodologies and instruments for assessment. 30 ,31 The selection of the AQ-D for the study of anosognosia was carried out based on the fact that it discriminates between patients with minimal alterations in awareness of the disease and patients who clearly present with anosognosia. Also, the AQ-D is a scale that was developed for detecting anosognosia globally, 19 incorporating the assessment of cognitive disorders, as well as functional and behavioral disorders. 18 Despite its use by different research groups, 32, 33 the use of the AQ-D in the context of clinical practice is not common and the clinical diagnosis of anosognosia continues to be through clinical anamnesis. One reason is that there is a lack of a gold standard test that allows for definite distinction between patients with and without anosognosia. Another limiting factor is the lack of a test that is easy to use and quick to administer. The AAQ satisfies these requirements and provides a more comprehensive and standardized way to assess anosognosia. The results reported here have shown that the AAQ is equivalent to the original scale and that it identifies the presence of anosognosia in patients with AD accurately. We note that the items selected in the AAQ correctly evaluate memory loss, an aspect that is frequently assessed in different scales for evaluating cognitive impairment in patients with AD. Remembering events or remembering the shopping list and the ability to use currency are items of the cognitive assessment (part A) of the Blessed Dementia Rating Scale (BDRS), 34 one of the scales most used in the diagnosis and follow-up of AD. The items remembering telephone calls and ability to carry out transactions are included in the functional evaluation scale of the DAD, 23 which is widely used in studies and clinical trials. Likewise, the items being more self-seeking and being more irritable are items that are a part of section C (behavioral subscale) of the BDRS.
The frequency and severity of the BPSD are high in patients with anosognosia. The AAQ correlates well with the presence of BPSD as previous studies have indicated, showing a high association with frontally mediated disorders. 11, 12 The 33.8% of the study patients who were in a mild or initial phase of disease stage were found to have a strong correlation between anosognosia and behavioral disorders including irritability, apathy, and disinhibition disorders associated with the alteration in the abilities of planning and organizing. 34 This aspect is important as the presence of dysexecutive disorders in the initial phases of anosognosia may lead to a greater exposure of the patients to higher risk behaviors and making poor decisions that may affect the patients themselves as well as the people around them. 2, 14 This highlights the importance of studying anosognosia in daily clinical practice, both for adjusting the pharmacological and nonpharmacological treatments as well as avoiding risky situations and adjusting strategies of psychoeducational support to relatives.
Scale abbreviation, which is typically done for scales that are used frequently, is a common technique that is done to facilitate the care and supervision of patients in clinical practice. Currently, there are condensed versions of scales as common as the NPI, the Geriatric Depression Scale, and the Burden Interview, among others, [34] [35] [36] [37] [38] which has made it easier to include them in research protocols, during clinical care, and during sociosanitary care. In addition to the AAQ being in agreement with the original scale, it has excellent rates of sensitivity and specificity. The new AAQ scale preserves the structure of 2 factors with the items, the first of which is associated with cognitive and functional abilities, and the second is related to behavior. Moreover, the correlations existing between the first factor (cognitive and functional) and the MMSE score and between the second factor (behavior) and the NPI score not only increase the discriminating validity of the factors but also support the decision to force the result of the first FA. It should be noted that while the cutoff point selected in the AAQ has high values of sensitivity and specificity compared to the original scale, it also has a greater sensitivity than the AQ-D, a feature that should be taken into account during the study of anosognosia.
One limitation in this AAQ validation study is that the sample set was not specifically selected for this purpose. However, the inclusion of patients with AD in different stages of disease progression was taken into account (as was the case in the original factor structure validation study). Another limitation was in the determination of the items of the AAQ, as there are multiple forms for this purpose. In this study, we prioritized the factor structure of the original scale presented with a composition of 2 factors. However, the indexes of concordance with the original scale demonstrate that the items selected are adequate and the factor structure has been maintained. Importantly, the number of items is sufficiently reduced to render the abbreviated scale more practical than the original scale. In addition, the 2 items comprising the 2-factor scale refer to aspects easily observed clinically in patients with dementia.
Currently, pressure on health care services makes it difficult to expand the study of patients, and the use of psychometric instruments is being reduced to the essential minimums. The incorporation and use of new scales are directly correlated with the time of administration and with the information it provides. 39 Under these circumstances, for the study of anosognosia, the use of the AAQ is advisable, as it allows a valid and reliable diagnosis to be reached more swiftly.
